Belite Bio (BLTE) CFO Chuang Hao-Yuan details options and shares in Form 3
Filing Impact
Filing Sentiment
Form Type
3
Rhea-AI Filing Summary
Belite Bio, Inc. director and Chief Financial Officer Chuang Hao-Yuan filed a Form 3 disclosing his existing equity holdings in the company. The filing lists several stock options to acquire ordinary shares, including options over 144,868 shares at an exercise price of $0.4386 per share expiring on December 22, 2030, and 26,112 shares at $6.00 per share expiring on April 17, 2032.
Additional options cover 120,834 ordinary shares at $14.45, 250,000 shares at $48.46, 200,000 shares at $54.88, 40,000 shares at $77.40, 80,000 shares at $93.02, and 150,000 shares at $158.36, each with expirations between 2033 and 2036. The filing also reports direct holdings of 100,000 American depositary shares and 195,264 ordinary shares, with each ADS representing one ordinary share.
Positive
- None.
Negative
- None.
Insider Trade Summary
10 transactions reported
Mixed
10 txns
Insider
Chuang Hao-Yuan
Role
Chief Financial Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | American depositary share | -- | -- | -- |
| holding | Ordinary Share | -- | -- | -- |
Holdings After Transaction:
Stock Option (right to buy) — 144,868 shares (Direct);
American depositary share — 100,000 shares (Direct);
Ordinary Share — 195,264 shares (Direct)
Footnotes (1)
- Each American depositary share represents one ordinary share, par value US$0.0001 per share, of the Issuer. The option to purchase 144,868 ordinary shares had vested prior to March 18, 2026. The option to purchase 26,112 ordinary shares had vested prior to March 18, 2026. The option to purchase 100,000 ordinary shares had vested prior to March 18, 2026. The option shall vest as to the remaining 20,834 ordinary shares in five monthly equal and continuous installments at the end of each month from March 2026 to July 2026, subject to continued service to the Issuer on each such date. The option shall vest as to 250,000 ordinary shares in 36 equal and continuous monthly installments for each full month of services completed following August 29, 2024, subject to continued service to the Issuer on each such date. The option shall vest as to 200,000 ordinary shares in 36 equal and continuous monthly installments for each full month of services completed following February 12, 2025, subject to continued service to the Issuer on each such date. The option to purchase 40,000 ordinary shares had vested prior to March 18, 2026. The option to purchase 80,000 ordinary shares had vested prior to March 18, 2026. The option shall vest (i) as to 50,000 ordinary shares on January 9, 2027, (ii) as to 50,000 ordinary shares on January 9, 2028, and (iii) as to 50,000 ordinary shares on January 9, 2029.
FAQ
What does Belite Bio (BLTE) CFO Chuang Hao-Yuan report in this Form 3?
He reports his existing equity holdings in Belite Bio, including stock options and common equity. The filing lists multiple option grants over ordinary shares plus direct ownership of American depositary shares and ordinary shares, giving investors a snapshot of his baseline ownership position.
What stock options does the Belite Bio (BLTE) CFO hold according to the Form 3?
The Form 3 lists several stock options to buy Belite Bio ordinary shares at exercise prices from $0.4386 to $158.36. Each grant specifies an expiration date between 2030 and 2036, outlining a long-dated incentive package tied to the company’s share performance.
How do the Belite Bio (BLTE) CFO’s option grants vest over time?
Footnotes describe specific vesting schedules. Some options, such as those for 144,868 and 26,112 ordinary shares, were fully vested before March 18, 2026, while others vest monthly over 36 months or in annual tranches through 2029, contingent on continued service.